Biogen Inc. (BIIB) Earnings Call Transcript & Summary

April 22, 2021

NASDAQ US Health Care Biotechnology earnings 61 min

Earnings Call Speaker Segments

Mike Hencke

executive
#1

Hello, and thanks for joining us for Biogen's earnings call covering the first quarter of 2021. Ahead of getting started, I'd ask that all of you visit the Investors area of biogen.com, where you can locate the earnings release along with the related financial tables — this includes our GAAP financial measures plus a reconciliation between GAAP and the non-GAAP financial measures we'll be talking about today. Tables 1 and 2 contain our GAAP financials, while Table 4 has a reconciliation of our GAAP results to non-GAAP financial results; in our view, non-GAAP financial results do a better job of representing the ongoing economics of our business and show how we manage things internally. We've also put slides up on our website that accompany the discussions tied to this call. I want to note that we'll be making forward-looking statements, which rest on our current expectations and beliefs; such statements carry certain risks and uncertainties, and our actual results could differ materially. For more detail, I'd encourage you to review the risk factors discussed in our SEC filings. Joining me on today's call are our Chief Executive Officer, Michel Vounatsos; Dr. Al Sandrock, Head of Research and Development; and our CFO, Mike McDonnell. One reminder: during the Q&A portion, we kindly ask that you limit yourself to one question. I'll now hand the call over to Michel.

Michel Vounatsos

executive
#2

Hello everyone, and thanks for being here today. Our attention remains squarely on operations and execution as we keep serving patients and moving our strategic goals forward. Although we recognize 2021 will be a year of financial investment for the company, our operational results in Q1 left us encouraged, with total revenues for the first quarter reaching $2.7 billion and non-GAAP ES for the first quarter at $5.34. Solid performance in MS, SMA, and biosimilars, along with ongoing disciplined cost management, produced these results. Should regulatory approval come through, we are prepared to launch aducanumab in the U.S., and we expect an FDA decision by the June 7 PDUFA date. If approved, aducanumab would become the first therapy to meaningfully alter the cost of Alzheimer's disease and would constitute a substantial opportunity for growth and value creation. Our cross functional team in the U.S. has spent months getting ready for a possible aducanumab launch. We have pinpointed and assessed key sites of care possessing the infrastructure Alzheimer's patients require. We believe more than 600 of these sites will be prepared to treat patients shortly after a potential approval. Right now our team is assessing capacity at these and other sites to handle an influx of Alzheimer's patients. Alongside Eisai, we were glad to back us against Alzheimer's in creating BrainGuide, a platform powered by Amazon Web Services. BrainGuide is meant to boost brain health awareness and enable people to act based on how they respond to a memory questionnaire. Our hope is that BrainGuide, together with our collaboration with Apple aimed at identifying digital biomarkers of cognitive health, will help people seek care earlier so they can get the most from treatment. We are also striving to guarantee an equitable launch that facilitates broad access to aducanumab, if approved, including underserved populations, a critical issue brought into focus by the COVID-19 pandemic. I am happy to share that beyond the U.S., we recently filed additional regulatory submissions in Brazil, Canada, Switzerland, and Australia, which add to our earlier filings in Europe and Japan. Turning to how we're doing on the strategic priorities: to start, total MS revenue for Q1, which includes royalties from OCREVUS, reached $1.7 billion. If you take out the U.S. launch of generic TECFIDERA, the rest of our MS portfolio continued to demonstrate both resilience and forward movement; outside of U.S. TECFIDERA, the number of patients using our MS treatments around the world grew about 5% year over year. What's more, in the setting of COVID-19 as it stands today, we feel our MS offerings are strongly placed relative to rivals, thanks to the treatment guidelines currently in effect; we were pleased by the strong revenue gains for VUMERITY, which is now the top oral MS therapy in the U.S. when measured by new prescriptions. From where we sit, these results show we have a solid product lineup and a team that knows how to get things done — which confirms the mid-last-year plan we shared for bringing VUMERITY to market faster. We're also glad that TECFIDERA has now received approval from regulators in China. Beyond that, we continue advancing fresh strategies meant to tackle the unmet medical need that still exists in MS. This quarter, we rolled out an intramuscular form of PLEGRIDY in the U.S; and EU, which in our view delivers improved tolerability, and we obtained approval for subcutaneous administration of TYSABRI in the EU, with the initial launch expected in Germany, while we await a regulatory decision in the U.S. We're still working to move forward on the possibility of using extended interval dosing with TYSABRI, and we expect key data around the midpoint of this year. Turning to SPINRAZA: global sales for the first quarter reached $521 million. Competition exists for SPINRAZA in the U.S., and the effects of COVID-19 have intensified that pressure, but it was encouraging that discontinuations of SPINRAZA declined compared with Q4 of last year. Outside the U.S., SPINRAZA continued to deliver strong results, with revenue up 13% compared with Q1 of last year. Taking everything together, SPINRAZA remains the top treatment on the market for SMA, and we expect it to remain a cornerstone of care. As for our biosimilars business, it recorded revenue of $205 million. This quarter's results are encouraging, especially given that COVID-19 continues to disrupt things — fewer immunology patients in Europe are beginning new treatments, and clinics there have less capacity to take them on. Our plan is to keep expanding the biosimilars side of the business while also freeing up more money to fund innovation through product launches. Along those lines, we shared news not long ago that we'd be working with Bio-Thera Solutions on developing and commercializing BAT1806, a proposed biosimilar that references ACTEMRA and is presently in Phase 3 development. Outside of China, Biogen will retain rights to sell BAT1806 around the world, extending where our biosimilars reach globally. And fourth, we kept up solid momentum on the pipeline during this quarter. We shared results from a Phase 2 study in essential tremor, and we're anticipating seven more readouts from mid-to-late stage programs during this year. Biogen sees gene therapy as a major priority as we keep advancing several different modalities. Along those lines, we just revealed our intention to construct a new cutting-edge gene therapy production plant at our RTP location in North Carolina. Fifth, our ability to generate cash is still robust, which keeps giving us considerable room to deploy capital in Q1. We brought in roughly $769 million in cash flow from operations, along with 676 million in free cash flow. We've shown before that our focus stays on delivering the strongest possible returns for shareholders while also working to get breakthrough treatments to people who need them. At this point, I'll hand things off to Al, who will walk everyone through a closer look at what we've recently achieved in research and development.

Al Sandrock

executive
#3

Thank you, Michel, and good morning to all of you. As I always do, I want to begin by expressing appreciation to the Biogen team for the effort they put in as we keep moving our R&D programs forward. During this quarter, we hit a number of important milestones, and we anticipate seven more readouts later this year, which include pivotal trials in major depressive disorder, postpartum depression, ALS, and choroideremia. Now let me discuss the progress achieved across our pipeline during the first quarter. Beginning with Alzheimer's disease, as Michel noted, we filed additional regulatory submissions for aducanumab this quarter in Brazil, Switzerland, Canada, and Australia. We've already filed in the U.S., EU, and Japan, and now we've also submitted in seven major markets. While regulators go through the aducanumab data, we're staying in touch with them. Moving on to lecanemab, also known as BAN2401: our partner Eisai just enrolled the last patient in the Phase 3 clarity trial for early Alzheimer's disease. We expect to see results in the third quarter of next year. Also, we plan to share detailed findings from the Phase 1b trial of BIIB080 in mild Alzheimer's disease at the AAIC conference later this year. BIIB080 is an antisense oligonucleotide that targets tau, aiming to reduce the production of all tau forms, whether inside or outside cells. According to results from the Phase 1b trial, BIIB080 was generally well-tolerated and led to reductions in CSF total tau and phospho-tau that depended on dose and time, measured from baseline, and the effect lasted. We're currently wrapping up our plans to advance BIIB080 into a Phase 2 study for Alzheimer's disease. Turning to MS, this week at the AAN meeting we're sharing new data from across our portfolio. A refreshed analysis of data from the TOUCH Prescribing Program for TYSABRI showed that when extended interval dosing, or EID, was used, there was an 88% drop in the risk of PML compared with standard interval dosing; this supports earlier results indicating that EID is associated with fewer cases of PML. With MS PATHS, we continue to produce top-tier real-world evidence. Through this initiative, Biogen collaborates with ten premier multiple sclerosis clinics across the United States and Europe, collecting uniform quantitative information from a varied group of MS patients during their visits to the clinic. So far, over 17,000 patients have signed up for MS PATHS. Our goal is to apply quantitative assessments spanning several important clinical areas — MRI measurements taken in high position that capture MS disease activity, data reported by patients through a validated quality of life tool, led biomarkers including neurofilament, and electronic health records — so we can build a fuller picture of MS and learn how drugs that are already approved are impacting outcomes in the real world. On top of that, by leveraging contemporary analytical approaches like machine learning, we're hoping to uncover new findings regarding the main subtypes and stages of MS, along with its pathogenesis. During the AAN conference, we presented findings from MS PATHS indicating that giving TYSABRI at longer intervals might preserve effectiveness similar to the usual schedule, based on how many new or growing T2 lesions appeared on MRI scans, measured through sophisticated imaging software we created alongside Siemens. An ongoing prospective trial called NOVA is evaluating how well extended interval dosing works, and we anticipate its top line data near the middle of the year. Additionally at AAN, a separate study using information gathered through MS PATHS showed that TYSABRI may produce meaningful clinical gains in mental and social health areas, measured by neuro qual, a validated tool assessing physical, mental, and social impacts reported by patients with neurological conditions. Among 11 out of 12 domains examined, the adjusted improvement rate was higher among those on TYSABRI compared to those on OCREVUS. Another item being shared at AAN is the initial real world review of patients given VUMERITY. This retrospective look at 160 individuals revealed that overall persistence proved high, with 88% still taking VUMERITY at eight months, and that stopping treatment because of GI side effects was uncommon at 3.8%; these findings come after a recent publication of EVOLVE-MS-2, a Phase 3 5-week randomized multicenter trial that evaluated GI tolerability for VUMERITY and TECFIDERA through self administered questionnaires. In that study, GI issues that interfered a great deal or severely with routine activities were reported by 9.5% of patients taking VUMERITY, compared with almost 29% of TECFIDERA patients. We believe VUMERITY's different tolerability profile is going to lead to improved adherence to therapy. In addition to the therapies we already have, we plan to leverage our MS pipeline to address what remains unmet in MS. That includes BIIB061, our oral remyelination program, BIIB091, our oral BTK inhibitor, and our next generation anti-VLA4 antibody, which is intended to build on TYSABRI's success in the high efficacy space. Turning to neuromuscular diseases, at this week's AAN meeting we are providing an update on the ongoing DEVOTE study, which is looking at a higher dose of SPINRAZA. Data from patients in the open-label Part A safety cohort, who were followed for as long as about five months, aligned with the known safety profile of the approved 12 milligram SPINRAZA dose. The safety picture emerging at the higher dose supports moving that dose forward as we explore whether it may deliver greater efficacy. We also added a new cohort to the Phase 1 trial of BIIB078, our C9ORF ASO being developed for ALS. Safety findings have supported going higher with the dose, which lets us more fully evaluate the therapeutic index. With that added cohort included in the Phase 1 study, a readout is now anticipated in the first half of next year. Moving on to neuropsychiatry, Sage Therapeutics released interim results last month from SHORELINE, its ongoing open-label Phase 3 naturalistic trial of zuranolone in major depressive disorder. Those findings showed that within the 30 milligram zuranolone group that finished the study, participants who had a favorable response to a first two-week course of treatment largely—about 70%—required only one additional zuranolone treatment or none at all over the course of the one-year study. SHORELINE additionally determined that following that two-week treatment period, a positive response, measured using the 17 item Hamilton rating scale for depression, was achieved by more than 70% of patients in the 30-milligram cohort along with 80% of those in the 50-milligram cohort. Across both the 30 milligram group and the 50 milligram group, the safety profile observed in SHORELINE matched what earlier reports had shown. In the 50 milligram cohort, events such as somnolence, dizziness, and sedation appeared with greater frequency, yet the intensity of those events was comparable to what the 30 milligram zuranolone treatment produced. From our perspective, this information gives added weight to zuranolone's possible therapeutic benefit, and later in the current quarter we expect results from the waterfall study of zuranolone in major depressive disorder. I'd now like to turn to movement disorders.

Al Sandrock

executive
#4

Together with SAGE, we shared news not long ago that SAGE-324, which also goes by BIIB124, hit its primary endpoint — a statistically significant decrease from baseline versus placebo in the upper limb tremor score, measured on pre-specified components of the Essential Tremor Rating Assessment Scale, or TETRAS, at day 29. That translated into a 36% drop from baseline in upper limb tremor amplitude among patients on BIIB124, against a 21% decrease for placebo. BIIB124's safety profile also looked consistent with what we'd reported before; this study was built to test the top of the dose range set in Phase 1 studies, 60 milligrams, aiming to see whether proof of concept could be shown in essential tremor. BIIB124 clearly demonstrates efficacy in essential tremor, yet at that dose, somnolence occurred in 68%, with 62% of patients moving to a lower dose and 38% stopping treatment altogether. We're collaborating closely with SAGE on planning the next steps for BIIB124's development. The unmet need in tremor — essential tremor — is substantial. No new drugs have won approval for essential tremor in over five decades. The therapies in use today for essential tremor carry tolerability problems of their own, which restricts how they're used in clinical practice; we think more can be done for patients with this most common movement disorder, one that interferes with activities of daily living and hampers social engagement. In Parkinson's disease, the Phase 1 and Phase 1b studies of BIIB122, a small molecule LRRK2 inhibitor, are now finished, and the safety and biomarker goals were met, which we believe supports continued development of BIIB122. As we previously announced alongside our collaboration partner Denali, we expect to launch late stage clinical development in Parkinson's disease patients by the end of this year. Our R&D organization achieved a number of important milestones in the first quarter of the year. We think there's a lot to be excited about, with seven additional readouts anticipated by the end of the year, including pivotal readouts in major depressive disorder, postpartum depression, ALS, and choroideremia. I'll now hand the call over to Mike.

Mike McDonnell

executive
#5

Appreciate that, Al. Despite the challenges created by TECFIDERA, U.S. generics, and COVID-19, Biogen turned in another solid quarter, and we continue to perform well across all of our core businesses. Our financial position is still quite strong, with plenty of cash and financial flexibility, and we intend to expand the business over the long haul. Now let me take you through the quarter's financial results and give you an update on our guidance for the full year 2021. Total revenue for the first quarter reached $2.7 billion, a decline of 24% versus last year at actual currency and 25% at constant currency. The main reason for that drop was the continued impact of TECFIDERA generics in the United States. For the first quarter, our total MS revenue—including $1.7 billion in OCREVUS royalties—dropped 26% year over year on both an actual and constant currency basis. The same factor drove this: generic TECFIDERA continuing to affect the U.S. market. When U.S. TECFIDERA is left out, total MS revenue with OCREVUS royalties included came in relatively flat, demonstrating the resilience of our MS business amid competition. Global TECFIDERA revenue for the first quarter reached $479 million, a 56% decrease from a year earlier. Outside the U.S., first-quarter TECFIDERA revenue came to $317 million, down 2% year over year. Once you account for about $28 million in accelerated COVID-19-related shipments during Q1 of 2020, revenue outside the U.S. climbed 7%, driven by sustained patient growth. Looking at the quarter overall, things moved in a positive direction for VUMERITY. We brought in $74 million from VUMERITY during Q1, and among oral MS treatments in the U.S., it's now ranked first for new prescription share. TYSABRI's global revenue for the first quarter came to $503 million, a 4% decline versus the same period last year. It's worth remembering that Q1 2020 included about $40 million in favorable impact for TYSABRI — a combination of extra U.S. shipping days and an Italy pricing adjustment. Once you strip out those factors, revenue was up 4% compared to a year earlier, and the number of TYSABRI patients worldwide grew 5%. We continue to view TYSABRI as favorably placed to take on a growing part in treating MS, since we're pushing forward on multiple important efforts, including giving it under the skin and dosing at longer intervals. Now I'll move to SMA. Global SPINRAZA sales for the first quarter reached $521 million, a decline of 8% year over year using actual currency, or 12% when currency is held constant, yet we took pleasure in seeing the number of SPINRAZA patients worldwide rise 5% compared with a year earlier; within the U.S., SPINRAZA revenue dropped 37% versus the same period last year, as rivals keep pressuring us and COVID-19's impact has made things harder. Outside the U.S., SPINRAZA revenue climbed 13% year over year, which includes roughly $40 million tied to the timing of shipments during the first quarter of 2021. Now let's discuss biosimilars. Sales in the first quarter reached $205 million, representing a 6% decline year over year in actual currency and 13% on a constant-currency basis. If you factor out roughly 15 million in accelerated COVID-19-related shipments during Q1 2020, the top line was unchanged compared with a year ago. Our biosimilars segment continues to face pressure on pricing, and the pandemic has led to fewer patients beginning new therapies along with reduced clinic capacity. Despite COVID-19's continuing impact, we hold the number one position among anti-TNF biosimilar providers in Europe, and BENEPALI remains the most widely prescribed etanercept product across the continent. We believe there is opportunity for further growth in Europe as well as in the U.S. and other geographies through launching new products. Anti-CD20 revenue for the first quarter totaled $389 million, a 25% drop from the prior year. RITUXAN revenue fell roughly 50% year over year, partly offset by a 29% rise in OCREVUS royalties; because of biosimilars, we anticipate RITUXAN will keep eroding. Now on to gross margin: it came in at 82% of revenue in the first quarter, lower than 83% in the prior quarter and lower than 87% in Q1 of 2020. That ongoing decline was mostly driven by drops in TECFIDERA and RITUXAN, two high margin products. We anticipate continued downward pressure on gross margins. Shifting to expenses and the balance sheet, non-GAAP R&D expense for the first quarter came to $514 million. On a non-GAAP basis, selling, general and administrative expenses came to $595 million during Q1. That figure contains approximately $75 million related to getting aducanumab ready for market, after subtracting Eisai's reimbursement contribution. For the first quarter, our effective non-GAAP tax rate stood at roughly 16%, versus approximately 17% during the same period in 2020. We repurchased 2.2 million shares of common stock in the company for $600 million in Q1. The share repurchase program authorized in October of 2020 had $4 billion remaining as of March 31, 2021, and we anticipate drawing on some of that amount during the remainder of the year. Our weighted average diluted share count for the quarter came in at approximately 152 million shares. For the first quarter, non-GAAP diluted EPS came in at $5.34. We generated roughly $769 million of cash from operations during that period. Capital expenditures totaled $93 million, which left us with free cash flow of approximately $676 million. When the quarter ended, our debt stood at $7.3 billion, while cash plus marketable securities amounted to $3.4 billion — putting net debt at $3.9 billion. Our $1 billion revolving credit facility also remained untouched at quarter's end. Turning now to the revised outlook we're providing for the full year 2021: revenue for the year is still projected between $10.45 billion and $10.75 billion, even with the currency headwinds I'll get into in a moment. We're lifting our non-GAAP diluted EPS outlook. It used to sit at $17 to $18.50, and now we're putting it at $17.50 to $19. On capital expenditure, our guidance stays where it was, at $375 million to $425 million. For this financial guidance, we're assuming foreign exchange rates from March 31, 2021 stay in place through the rest of the year, net of hedging activities. One thing I'd like to stress: our revenue outlook isn't moving, even though we expect a hit of about $80 million tied to currency, net of hedging, against our full-year 2021 revenue guidance. The main reason is that between January 1 of 2021 and March 31 of 2021, the U.S. dollar got stronger. Our guidance still presumes that aducanumab will receive U.S. approval by June 7 of 2021, though the FDA's decision remains uncertain. Should aducanumab get approved in the U.S., we would anticipate launching it right away. That said, dose titration will mean lower revenue per patient during the first months of treatment, so we would anticipate only modest aducanumab revenue in 2021, with growth afterward. We still anticipate swift erosion of our U.S. TECFIDERA business, along with substantial erosion of RITUXAN in the U.S.; we anticipated that falling revenue from these high margin products would squeeze our gross margin percentage. Keep in mind that our gross margin in Q1 2021 came to 82% of revenue, which captures this dynamic. Our full-year outlook for non-GAAP R&D spending is now $2.3 billion to $2.4 billion, while non-GAAP SG&A is expected to land between $2.6 billion and $2.7 billion. Built into this guidance is our assumption that both R&D and SG&A will climb beginning in Q2, reflecting new collaborations, program readouts, and investments in aducanumab as we prepare for a possible launch. Within our full-year SG&A figure, we still assume about $600 million goes toward supporting the potential aducanumab launch. Of that amount, roughly $200 million would be reimbursed by Eisai and, once commercialization occurs, would appear as collaboration profit sharing instead of sitting inside SG&A. We expect to deploy a portion of the $4 billion still available under our share repurchase authorization during the year, but several considerations will determine whether we do so, including what happens with our business development efforts. Our guidance does not include any impact from possible tax or healthcare reform, and it also excludes any impact from possible acquisitions or major business development deals. With that, I'll return the call to Michel for his closing remarks.

Michel Vounatsos

executive
#6

Thanks, Mike. In the first quarter of this year, Biogen again showed its resilience along with solid execution. We think we're still positioned to make 2021 a year of transformation for the company. Naturally, that begins with the possibility that aducanumab gets approved in the U.S. The unmet need tied to Alzheimer's disease, along with what it costs society, is enormous and growing. In the U.S., Alzheimer's imposes a cost burden exceeding $600 billion each year, while caring for Alzheimer's patients can run over half a million dollars — that is, over $0.5 million. Alzheimer's robs many patients of their independence. Roughly 75% of those with Alzheimer's disease are leaving the nursing home by age 80, at a probation cost of about $100,000 annually. Should aducanumab be approved, it would mark an unprecedented milestone for patients, their families, and society as a whole. Past aducanumab, we keep moving our neuroscience pipeline forward in pursuit of a multi-franchise portfolio; we anticipate seven mid-to-late stage readouts during this year. These span therapeutic areas including Alzheimer's disease, ALS, ophthalmology, depression, and stroke, with four of them in Phase 3. I'd like to restate our commitment to delivering maximum returns to shareholders and to bringing patients innovative therapies over the long term; achieving that requires us to keep allocating capital in an efficient and effective way, while preserving operational discipline and controlling costs. As shown previously, we will always aim to hold an optimal capital position, and to seek superior returns on the investments we undertake. Finally, I want to acknowledge Biogen's enduring commitment to corporate responsibility. Our dedication to patients and to society more broadly isn't confined to creating novel therapeutics for those suffering from serious diseases — it reaches much further. Here at Biogen, we pursue our work with purpose, advancing science to meet the urgent, long-term challenges humanity faces. Now, more than at any time, we keep reinforcing environmental, social, and governance priorities throughout the company. To highlight that commitment, we've chosen to add an ESG metric to our corporate scorecard, which will help make sure we speed up action on these critical issues. To wrap up, I want to thank our employees worldwide, who've shown dedication to creating a positive impact on patients' lives, along with all the physician caregivers and participants in our clinical development programs. With COVID-19, we're living through difficult times, and our accomplishments wouldn't be possible without passion and commitment. We'll now take questions on the call.

Michael Yee

analyst
#7

Hi everyone, good morning, and I appreciate you taking the question. You sound pretty confident that adu could get approved, so I wanted to ask whether you could share some thoughts on what you've been doing with the sites as well as the payers? My understanding is that should approval come through, plenty of uncertainty exists regarding pet reimbursement, logistics, MRI monitoring, and similar matters, so perhaps you could speak to the efforts made on that front and how sure you are things will go reasonably smoothly? Thank you.

Michel Vounatsos

executive
#8

Michael, thank you for asking. For many months now, the team's priority in the U.S. has been, first, to locate and support the sites of care with infrastructure guidance and processes, since we expect that, upon approval, there will be a very large wave of patients. We recognize that specialist availability and diagnostic capacity represent a bottleneck. Therefore, we needed to get the sites of care ready, and we've been working across the entire country to find those today. Our expectation is roughly 600 that are ready to treat, though many additional ones are in progress. A cross functional team oversaw this effort, and clearly we began with medical engagement and scientific leadership. We're happy with where we stand regarding those sites, along with the capacity to welcome patients, diagnose them, dose them, and monitor them, covering even detailed processes like formula releasing and who handles which task. Thus the team has carried out very meticulous work, and each time I go over the U.S. operation and launch readiness, I'm happy with the progress. We're bridging, we're clearing some new milestones. I'm also happy with the digital capability that serves as an overlay for reach, contact, and awareness building toward various stakeholders, including not just physicians but patients and end-patient services too. As you're aware, up to now, neither PET nor CSF amyloid gets reimbursed in the U.S. CSF does get reimbursed in Europe, though not in the U.S., yet we believe a path forward exists. On the matter of price, I'd say we're set there, Mike. We've carried out a thorough engagement with various stakeholders, taking into account the disease burden and the clinical meaningfulness that aducanumab will deliver. And we've engaged with pharmacoeconomics, ICER included, on many occasions, plus others in the U.S. and beyond; so I believe the team is prepared, and I'm happy with the progress. In fact, the three months edition felt like a gift to the team, since one is never fully ready for a launch like this; and I should also acknowledge Eisai's collaboration on this launch readiness.

Michael Yee

analyst
#9

Yeah. Great. Can't wait. Thanks a lot.

Ronny Gal

analyst
#10

Hello there. Morning, everyone, and I appreciate your time on this call. My first question concerns TECFIDERA. If you manage to prevail in the appeal or secure an unusual patent, could you walk us through the effect that would have on the market? Specifically, I'm aware you've reached a handful of settlements, and what I'd like to know is whether those products would remain in the market, or would they be forced to leave if your agreements — if you end up winning the appeal?

Mike McDonnell

executive
#11

Yes. Ronny, this is Mike. Thanks for asking. As we've mentioned, we anticipate some news regarding the appeal during the first half of this year. Given that today is April 22, it could arrive at any moment. As you're aware, there are numerous generics currently in the market, and our legal team has put in tremendous effort attempting to secure a win on this appeal and get the decision reversed. If we do succeed, clearly that would be terrific news on the appeal front, but additional progress would follow from that point. Consequently, trying to quantify any potential financial upside would be premature and difficult to do right away. This would be the kind of scenario where we'd receive the favorable outcome, and then we'd need to work through a series of further steps before reaching finalization, including how the generics presently in the market might respond. That's somewhat difficult to foresee before it actually occurs. So I'd say that clearly it would be a great day and great news, and we're putting in a lot of effort, and we have faith in our case. But we'd need to, in a sense, assess the ruling and what it states. And we'd share more regarding potential benefits as soon as we understood what that path looked like.

Ronny Gal

analyst
#12

Let me press you on this a bit further — are there any settlements in place that would let a generic remain on the market for a longer stretch of time, even in the event that you prevail?

Mike McDonnell

executive
#13

Yeah, that's not really a topic we're able to address with any specificity, Ronny. Again, yeah, we're — and I'm sorry about that. But this is a situation where, once more, we've got an excellent legal group putting in tremendous effort and getting this appeal overturned, and we're quite optimistic that we'll hear something in the near term, and we'll share more about precisely what it all means. We would need to examine the ruling along with the particulars, and we'd have to observe how the generics currently in the market respond before we could genuinely provide that answer.

Ronny Gal

analyst
#14

Right. Appreciate it.

Mike McDonnell

executive
#15

Thanks for the question.

Marc Goodman

analyst
#16

Yes. Good morning. Could you provide additional detail regarding SPINRAZA in markets outside America, and perhaps discuss certain areas—specifically, what underlying patterns exist and what is happening in them? Then regarding TECFIDERA, China, could you assist us—are sales being recorded? Do you consider that a significant opportunity? Thanks.

Michel Vounatsos

executive
#17

Thanks for the question. We are extremely happy with how SPINRAZA has done abroad, and I am equally happy with how it has performed domestically, even though, as you know, we encountered some patients stopping due to the combined impact of COVID, as well as the perceived improved modality involving the <<inaudible>> the convenience; therefore, much learning is emerging from America that can be applied to Europe and beyond Europe. A very robust resilience is visible in key European markets, and we observe quite rapid growth momentum across emerging geographies. Thus, on the whole, I am extremely pleased. Looking ahead, I think that as the pandemic situation improves and more people get vaccinated, hesitancy about going into institutions will gradually fade. And the <<inaudible>> data continues to reinforce the <<inaudible>> that basically this product isn't particularly troublesome for kids above the age of five. The cap on dosing, for all the reasons everyone knows about, more or less sets where efficacy tops out, while the body weight of young adults or toddler-aged young adults goes up — and that group makes up the largest portion of the market, and it's also where we've seen some switching. So obviously, whatever we learn here in the U.S. will probably benefit people outside America in a context where we should be dealing with less of the pandemic. I'm pleased to see developing markets finally paying attention to rare diseases after years of being overlooked, and now they're getting included in budget discussions, which shows great progress. When it comes to TECFIDERA in China, that marks Biogen's second approved medicine there, and I couldn't be more excited. You may know that I spent four years living in that country with my family while working for my previous employer, and I have strong faith in what this market can achieve over time—it already ranks as the second largest globally, so the need is enormous. Meanwhile, epidemiological data is growing quickly and starting to mirror patterns seen in the West. For MS specifically, the rate of new cases is smaller, yet the patient population still exceeds 100,000. Diagnosis rates, along with treatment rates for the DMTs, are incredibly low — under 5% of the market. As a result, disability levels remain high, which creates a tremendous opening to build TECFIDERA alongside the remainder of the portfolio, ideally with a little more time. For Biogen, China matters a great deal. Asia-Pac is run out of China together with Japan, and we've entered a partnership with a Chinese firm regarding a biosimilar. So it's a geography we invest in. Of course, our focus remains on all the other areas as well, but China's momentum is powerful, and we have a fantastic team of more than 200 people based there. We're only at the beginning of this. Thank you for the questions.

Yatin Suneja

analyst
#18

Hi there. Thanks for letting me ask. My question concerns zuranolone; could you discuss what you anticipate from the waterfall study that's coming up? Why durability matters, and how are we supposed to think about durability past that 14-day treatment window? Is it necessary to <<inaudible>> you know, past Day 15, and in what way would the powering be set up following the primary endpoint? Thanks.

Al Sandrock

executive
#19

Hello, Al here. Right, so efficacy at Day 15 serves as the primary endpoint. Then a key secondary endpoint, so to speak, is durability at Day 42. And there are, you know, 2 ways of viewing it. First, does it remain distinct from placebo, or maybe even more crucially, what occurs from Day 15 through Day 42 regarding efficacy on the HAM-D score among treated patients. So I believe that based on earlier precedents, the second of those is likely more significant than the first. Still, I think both must be examined; and then naturally, the crucial durability evidence stems from SHORELINE data, which demonstrates that patients responding to the initial course of treatment require no more than 1 further treatment, with roughly 70% requiring no more than 1 further treatment across a full year. Thus, I'd say both types of durability matter.

Umer Raffat

analyst
#20

Hello, and thank you very much for fielding my questions. Michel, Michael, I'd simply like to get a clearer picture of how share buybacks have been trending. Specifically, I'm focused on the more than $10 billion of repurchases executed from 4Q 2019 through 3Q 2020, compared with roughly a billion carried out across 4Q 2020 and 1Q 2021. I'm just trying to grasp that decline in size more fully. And I recognize we can't really tie it to any single factor, but I'd really appreciate hearing the thinking behind it.

Mike McDonnell

executive
#21

Umer, this is Mike. Appreciate the question; so, a few points. What I'd say is that, you know, we repurchased $600 million during the quarter, and our commitment to the share repurchase program remains very strong, and we still view our stock as a highly accretive investment, and we'll keep buying back shares and deploy part of the remaining $4 billion authorization over the balance of the year, as we've stated. You know, looking back over five years, Biogen bought back roughly 71 million shares, totaling $20 billion in value; and I'd say we've definitely taken advantage of a terrific opportunity there. And I think you do need to distinguish between the levels of cash flow before generics entered for TECFIDERA. Clearly, that was a highly profitable product with a large U.S. revenue base, which is now eroding quite rapidly. So, we no longer have the free cash flow level we enjoyed before that, but even so, we still hold a meaningful amount of cash, with $3.4 billion on hand at quarter's end; and our commitment to share repurchases remains very strong. There's obviously a difference in the free cash flow level, and at various points we had a lot of excess cash on hand, even more than today, before the generic situation arose. So, within the limits of what's possible for us, we stay very committed. 600 million is still quite a meaningful figure. And we'll keep assessing a very robust pipeline of BD opportunities; we'll keep investing in those, you probably saw we announced an investment in a biosimilar opportunity with BioThera that we're excited about, and we'll keep repurchasing shares; and we have the means to do so; so, I wouldn't read too much into the volume as indicating we aren't committed to it, because it's something we continue to view as a highly accretive investment.

Matthew Harrison

analyst
#22

Thanks, and good morning. Al, I'd like to hear your thoughts on tau. Considering the findings that have come out of certain other trials, how confident are you about the data we're about to see in this area? Appreciate it.

Al Sandrock

executive
#23

Yes, hello Matthew. So the compound in question is gosuranemab BIIB092, our antibody directed at what is basically extracellular tau, aiming to stop tau from moving between cells. And you're correct — those negative results from Roche certainly give us reason to believe that going after tau with an antibody is a difficult endeavor. Even so, we haven't lost hope; the data from our own Phase 2 trial hasn't been seen by us yet. This is a big trial — over 650 patients, with multiple doses being evaluated. And the population we're studying is early-stage Alzheimer's, so I'd call it a strong study, one that will support a solid go or no-go call regarding Phase 3. In my prepared remarks I brought up BIIB080, since it takes a different tack against tau. This one employs an antisense approach to lower how much tau gets produced, and it ought to impact tau in both its intracellular and extracellular forms. That's a quite distinct strategy, and the Phase 1 findings have us enthusiastic — specifically the dose- and time-dependent decrease in tau expression observed in the CSF — and we can't wait to present those findings at a scientific meeting later this year.

Brian Abrahams

analyst
#24

Hey everyone, I really appreciate you letting me ask something. Regarding aducanumab, could you walk us through once more what the Phase 3 safety monitoring obligations looked like in those trials, and share whatever your current thinking is about the ideal approach once it's out in the real world? I'm also curious what sort of readiness sites would need on the management and monitoring side, plus how you'd go about getting the best possible benefit-risk balance for patients beginning adu. Thanks.

Mike McDonnell

executive
#25

Hello Brian. ARIA-E is the primary adverse event tied to adu. It can be tracked quite easily using a very routine MRI scan sequence. During the Phase 3 study, the bulk of the — practically all monitoring took place over the initial 12 months of therapy, since ARIA risk declines over time; the longer someone stays on treatment, the lower their chance of developing ARIA-E; and my recollection is that we ran either 6 or 9 scans across the trial. Still, our view is that such a high number won't be necessary. We chose to be especially careful in our Phase 3 studies, and the exact quantity required will clearly hinge on the conversations we have, should we reach them, or at the point we reach them, regarding the label, which isn't available to us at this time. Worth keeping in mind that the majority of ARIA-E cases showed no symptoms. Roughly two-thirds had no symptoms, I'd say. Where symptoms did appear, they tended to be on the mild side, things like headache and confusion. So my sense is this is an adverse event that can be handled and managed without much difficulty. And as for the sites — since nearly all, I mean practically every center, including private practice clinics, can get — has ready access to MRI, and like I mentioned, the sequence is a standard one; so monitoring for ARIA shouldn't pose a significant challenge, in my view.

Colin Bristow

analyst
#26

Morning, and congratulations on the quarter. Regarding the EMBARK trial, my understanding is that you cut the planned enrollment from 2,400 down to 1,800. I was curious whether you could shed some light on what drove that change. Was enrollment slow relative to what you expected? But the thing I most want to know is whether you have any data on enrollment rates in the feeder trials, comparing the aducanumab arms with the placebo arms? Thanks.

Mike McDonnell

executive
#27

Yeah, I appreciate the question. EMBARK is enrolling, and the pace is actually in line with what we predicted — it's on track. But as you pointed out, the overall number of patients we planned to enroll came down. The primary driver there was that many patients who were seeking to enroll in EMBARK did not meet certain eligibility requirements, medical eligibility requirements. That said, I'd note that interest among patients, and among investigators as well, is still high. And as I mentioned, enrollment remains on track. As for whether there's differential enrollment across the different feeder arms, I don't have that data.

Evan Seigerman

analyst
#28

Hello everyone, and thanks for letting me ask. I'd like to discuss the latest data release for SAGE-324. Although the primary endpoint produced a statistically significant finding, the discontinuation rate within the treatment group was notably high. I have two questions: could you remind us of your strategy to reduce that problem in a pivotal study? Also, for a commercially viable product in <<inaudible>>, what somnolence rate would be considered acceptable? Thanks.

Mike McDonnell

executive
#29

As I mentioned during my remarks, you're right that the primary endpoint was achieved, and I'd like to congratulate my SAGE colleagues on that — it's a significant outcome. Given that we explored the upper portion of the dose range, the clear next step is to determine if lowering the dose could lessen some adverse events without losing effectiveness. Additional strategies might involve altering the dosing schedule — for instance, gradually increasing to a target dose through titration — and we could also examine important subgroups. Regarding what's acceptable? That's genuinely difficult to answer with certainty. Each patient weighs the benefit they get from a medication against the side effects they must tolerate. Often it's a daily judgment call for patients, and here they can observe their own tremor symptoms. Maybe multiple dose options will eventually exist, letting patients select the dose that best balances benefit and risk for themselves.

Michel Vounatsos

executive
#30

Evan, my sense is that where we are in development right now, the team's mindset is to aim for results superior to what this initial Phase 2 showed — roughly 60% symptomatology and about 30% discontinuation. So that's an intriguing question you raised; it really comes down to benefit risk, but the mindset is that you ought to aim higher.

Jay Olson

analyst
#31

Hello, and thank you for taking my question. I'd like to ask about your subcutaneous approach. When it comes to subcu TYSABRI, do you view it as something that adds to IV TYSABRI, or as a replacement that will ultimately take the place of IV TYSABRI? Also, given that a study was conducted on subcu aducanumab, could you remind us what your plans are for a subcutaneous version of aducanumab, and how the experience you gain from subcu TYSABRI will be brought over to aducanumab?

Michel Vounatsos

executive
#32

Thank you for that question. The momentum behind TYSABRI has us very enthusiastic — its high efficacy and a mechanism that, in today's setting, is perhaps slightly preferred over beta cell depleters. The stigma surrounding TYSABRI, as you know, was always the PML risk, and with the data we've produced, along with the extended interval dose and, we hope, the data from the Nova study media readout, we ought to truly clarify the optimal dose and above all the frequency of treatment. Subcu gives us a chance to widen the target. If we examine the prescriber landscape for TYSABRI, which has been a tremendous success, it is extremely limited. Is that due to the infusion centers? Is that due to the PML risk? Likely both. In this case, we're bringing together the chance to access high efficacy with subcutaneous dosing. So, we ought to be positioned to expand the use and the targeting for TYSABRI.

Geoff Meacham

analyst
#33

Hi everyone, morning, and I appreciate you taking the question. Regarding adu, I'm simply wondering whether you've given the regulator additional materials — I wasn't certain about the specifics coming out of the EMBARK study. We're getting factor. Then, very briefly on tau, Al, I'd like your perspective on the tau imaging that Lily performed, just for the purpose of evaluating how severe Alzheimer's disease is — do you see that as something that, further down the line, might be brought into your trials? Thanks.

Al Sandrock

executive
#34

Hello, Jeff. Yes, we're still on schedule for the June 7 PDUFA date, and clearly, had we handed over significant extra data, that would have an impact on it. Beyond that, though, we'd rather not say anything about what we're, you know, sending in or our dealings with FDA, other than to note that meetings with them keep happening on a regular basis. From where we sit, all is proceeding as planned toward a PDUFA decision no later than the PDUFA date. When it comes to tau, the notion of leveraging tau imaging basically to determine a patient's stage is quite an intriguing and original idea. And they demonstrated that specific — should you examine amyloid pet alongside tau pet, it may be possible to select patients at the appropriate stage of Alzheimer's disease who'd gain the most from an agent that lowers amyloid, like donanemab and perhaps aducanumab and BAN2401. So I'd call it a really compelling concept. I believe it's one we ought to revisit through additional research, yet it holds potential to be helpful.

Sumant Kulkarni

analyst
#35

Morning, and thanks for the question. Since you're involved so closely in the FDA's review of aducanumab, aside from maybe the Alzheimer's disease stage that patients are at, what do you currently think or expect regarding particular restrictions and labeling for adu — say, based on APOE4 carrier status, or other variables that lean more genetic?

Mike McDonnell

executive
#36

Yeah, I'd like to be able to, but questions like those simply aren't ones I can address. Our review process is still ongoing. And I'm aware that we're under review, so I'm hoping that soon, one day, I'll be in a position to talk about all of that with you.

Sumant Kulkarni

analyst
#37

Thanks.

Michel Vounatsos

executive
#38

I'd like to express my appreciation to everyone for being on the Biogen call today. Our attention stays fixed on executing flawlessly and on our operation so that we can meet the guidance we've provided. Beyond that, we're concentrating on how quickly our pipeline is moving. Looking at the near term, we feel a great deal of enthusiasm about key readouts and, clearly, about a regulatory decision of critical importance regarding aducanumab. Enjoy the rest of your day.

Operator

operator
#39

Appreciate it. That brings us to the end of today's session. Thanks for joining us. You're free to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.